Enibarcimab
Based on 1 publication(s) in Google Scholar
Enibarcimab is a humanized, non-neutralizing monoclonal antibody targeting adrenomedullin (ADM). Enibarcimab binds to the N-terminus of ADM, retains ADM in the circulation, and mobilizes interstitial ADM to increase the level of active bio-ADM, ultimately stabilizing blood vessels. Enibarcimab can be used in research related to septic shock and acute heart failure.
Para uso exclusivo en investigación. No vendemos a pacientes.
- Pureza : 99.68%
- No. CAS: 2305638-98-4
- Peso molecular:145.82 kDa
-
Almacenamiento:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Actividad biológica
-
Chemical Information
- Protocolo
- Pureza y Documentación
- Referencias
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Enibarcimab
More
Actividad biológica
Descripciòn
Isotype
Human IgG1 kappa
Recommend Isotype Controls
Species Reactivity
Human
IC50 & Target
Adrenomedullin
In Vitro
Enibarcimab binds to the N-terminus of ADM with high affinity to form a complex. The Enibarcimab-ADM complex cannot freely cross the endothelial barrier into the interstitial space, leading to the accumulation of bio-ADM in the vascular lumen, thereby stabilizing the vascular barrier and reducing edema and congestion[1][2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Gene ID
Accession
Conjugated
Unconjugated
Reconsititution
The product can be reconstituted/diluted with sterile PBS or saline.
Format
-
Human IgG1 kappa
Aplicación
ELISA, FACS, Functional assay
Verified Bioactivity
-
Immobilized Adrenomedullin/ADM Protein, Human can bind Enibarcimab. The EC50 for this effect is 11.77 ng/mL.
Chemical Information
-
No. CAS 2305638-98-4
-
Appearance Liquid
-
Peso molecular 145.82 kDa
-
Color Colorless to light yellow
-
SMILES
[Enibarcimab]
-
Envío
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Almacenamiento
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (1)
-
Journal Impact Factor
-
Most Recent
Pureza y Documentación
-
Ficha de datos (257 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
Referencias
[1].
Knothe C, et al; ADRENOSS-2 Investigators. Enibarcimab for the treatment of septic shock in patients selected by a combination of the biomarkers bio-ADM and DPP3: A prespecified subgroup analysis of the AdrenOSS-2 trial. J Crit Care. 2025 Aug;88:155077.
[Content Brief]
[2]. Hartopo AB, et al. The ADESTE trial: A phase 2 study of enibarcimab, a monoclonal antibody targeting adrenomedullin, in acute heart failure. ESC Heart Fail. 2025;12(3):1848-1860. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Enibarcimab Related Classifications
HY-P99177 Related Classifications
Powered by Bioz